Princeton Global Asset Management’s Arbutus Biopharma ABUS Stock Holding History

Princeton Global Asset Management’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-2,000	Closed	-$4K	–	546
2022 Q3	$4K	Hold	2,000	–	–	﹤0.01%	462
2022 Q2	$5K	Sell	2,000 -3,600	-64%	-$9.21K	﹤0.01%	463
2022 Q1	$17K	Buy	5,600 +3,600	+180%	+$11K	﹤0.01%	377
2021 Q4	$8K	Hold	2,000	–	–	﹤0.01%	422
2021 Q3	$9K	Hold	2,000	–	–	﹤0.01%	411
2021 Q2	$6K	Hold	2,000	–	–	﹤0.01%	446
2021 Q1	$7K	Hold	2,000	–	–	﹤0.01%	405
2020 Q4	$7K	Buy	+2,000	New	+$7K	﹤0.01%	409

Other funds holding ABUS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

WCM

Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

FourWorld Capital Management New York $196M AUM 42.39% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Princeton Global Asset Management's ABUS Position: Q4 2022 in Review

Princeton Global Asset Management sold out of Arbutus Biopharma (ABUS) in Q4 2022, closing a stake of 2,000 shares — an estimated $4K sold.

Princeton Global Asset Management first reported a position in ABUS in Q4 2020 and held it in 8 quarters. The position peaked at $17K in Q1 2022. 114 funds tracked by Wall St. Rank hold ABUS as of Q4 2022.

Princeton Global Asset Management reported no remaining Arbutus Biopharma position as of Q4 2022 after selling out during the quarter.
Princeton Global Asset Management sold 2,000 Arbutus Biopharma shares in Q4 2022, an estimated $4K.
Princeton Global Asset Management first reported a position in Arbutus Biopharma in Q4 2020 and held it in 8 quarters.
Princeton Global Asset Management's Arbutus Biopharma position peaked at $17K in Q1 2022.
114 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q4 2022.

Based on Princeton Global Asset Management's 13F filing for Q4 2022, filed 6 Feb 2023.